Aetna Adds Coverage Policy for Prademagene Zamikeracel (Zevaskyn) — CPB 1084 Updated March 2026
Aetna, a CVS Health company, has issued a modified clinical policy bulletin for prademagene zamikeracel (brand name Zevaskyn), a cell-based gene therapy approved for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The update to CPB 1084, effective March 14, 2026, establishes Aetna's formal coverage position on this therapy—one of the most complex and high-cost biologics to enter the rare disease space in recent years. Billing teams at dermatology practices, academic medical centers, and specialty infusion facilities should review their workflows now before claims hit.
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Prademagene Zamikeracel (Zevaskyn) — CPB 1084 |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-03-14 |
| Impact Level | High |
| Specialties Affected | Dermatology, Wound Care, Hematology/Oncology, Rare Disease/Specialty Pharmacy, Academic Medical Centers |
| Key Action | Confirm prior authorization requirements and medical necessity documentation are in place before scheduling Zevaskyn administration for any RDEB patient. |
What Is Prademagene Zamikeracel (Zevaskyn) and Why Does This Aetna Policy Matter?
Prademagene zamikeracel (Zevaskyn) is an autologous, COL7A1 gene-corrected keratinocyte sheet therapy developed by Abeome (formerly Castle Creek Biosciences). The FDA granted approval in May 2024 for the treatment of wounds in adults and pediatric patients six years of age and older with RDEB—a rare, severely debilitating genetic skin disorder characterized by fragile skin, chronic non-healing wounds, and significantly reduced quality of life.
This is not a standard biologic infusion. Zevaskyn involves a manufacturing process using the patient's own skin cells, genetic correction ex vivo, and surgical grafting. That complexity means the billing and prior authorization pathway is unlike anything most RCM teams have encountered before. Aetna's decision to formally address this therapy under CPB 1084 signals the payer is preparing for coverage requests and setting the terms under which it will—and will not—pay.
Any facility or practice that treats RDEB patients covered by Aetna commercial or Aetna Medicare Advantage plans needs to understand this policy's parameters before initiating the treatment process.
Aetna CPB 1084: Coverage Framework for Zevaskyn
Because no detailed policy summary was available in the source data at the time of publication, the specific medical necessity criteria language from CPB 1084 has not been reproduced here. Billing teams and clinical staff should access the full policy text directly through Aetna's clinical policy bulletin library or via the PayerPolicy platform at the link below.
That said, based on Aetna's standard approach to gene therapy coverage and the FDA-approved indication for Zevaskyn, here is what practices should anticipate this policy to address:
Covered use (conditional): Aetna is expected to cover Zevaskyn for adults and pediatric patients (≥6 years) with a confirmed diagnosis of RDEB with chronic wounds, subject to prior authorization and documentation of medical necessity. Confirmation of the underlying COL7A1 genetic mutation via genetic testing is likely required.
Non-covered or investigational use: Applications outside the FDA-approved indication—including use in patients with other subtypes of epidermolysis bullosa (e.g., dominant DEB, junctional EB, or simplex EB) or in patients under age six—are likely to be deemed experimental/investigational until additional clinical data support coverage expansion.
Prior authorization: Given the therapy's cost profile (estimated at over $3 million per treatment course) and the narrow indication, prior authorization will almost certainly be required for every case. Expect Aetna to require documentation from a dermatologist or specialist experienced in RDEB management.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
The policy document for CPB 1084 as provided to PayerPolicy does not list specific CPT, HCPCS, or ICD-10-CM codes. Billing teams should monitor Aetna's code mapping documentation directly, as a dedicated HCPCS code for prademagene zamikeracel may be assigned or updated following the policy's effective date.
For reference, the relevant diagnosis coding for RDEB that clinical staff should be prepared to document includes:
| Code | Description |
|---|---|
| Not listed in policy data | See Aetna CPB 1084 directly for confirmed applicable diagnosis codes |
Until Aetna publishes confirmed code assignments for Zevaskyn, billing teams should contact their Aetna provider relations representative to confirm the appropriate HCPCS billing code and any required modifiers. Using an unverified code on a claim for a $3M+ therapy is not a recoverable error.
Prior Authorization and Medical Necessity Documentation Checklist
Gene therapies like Zevaskyn require a level of clinical documentation that goes well beyond a standard prior auth request. When submitting to Aetna, prepare to include at minimum:
| # | Covered Indication |
|---|---|
| 1 | Confirmed RDEB diagnosis with documented genetic testing confirming a pathogenic COL7A1 mutation |
| 2 | Wound assessment documentation (size, chronicity, prior treatment history) |
| 3 | Treating physician's attestation that the patient meets the FDA-approved indication (age ≥6, RDEB diagnosis, presence of wounds) |
| 4 | Documentation that conventional wound management has been attempted or is insufficient |
| 5 | Facility credentialing confirming the site is capable of administering a gene therapy product requiring surgical application |
Missing any of these elements will almost certainly result in a denial—and for a therapy with this price tag, an appeal process measured in months rather than weeks.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Pull the full CPB 1084 text immediately. Access the complete policy at Aetna's CPB library and route it to your dermatology or rare disease billing specialist. Do not rely on this summary alone for claims submission decisions. |
| 2 | Contact Aetna provider relations within the next 30 days to confirm the billing code (CPT or HCPCS) Aetna will accept for prademagene zamikeracel administration and any required modifiers or place-of-service requirements. Document the name of the representative, the date, and the call reference number. |
| 3 | Build a prior authorization packet template now. Before your first Zevaskyn case arrives, create a standardized documentation package that includes genetic confirmation, wound documentation, prior treatment history, and physician attestation. A missing document on a multi-million-dollar claim is a cash flow crisis. |
| 4 | Identify your Aetna Medicare Advantage population separately. MA plan coverage policies can differ from commercial CPBs—verify whether this policy applies uniformly or if MA plans follow a different review pathway. |
| 5 | Flag existing RDEB patients on your schedule. If you have patients with a confirmed RDEB diagnosis currently covered by Aetna who may be candidates for Zevaskyn, proactively initiate the prior auth conversation with their treating physician now rather than after a treatment decision has been made. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.